James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017 recipient of the Stanley J. Korsmeyer Award given by the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected honor societies for physician-scientists.

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

The Vanderbilt Digestive Disease Research Center (VDDRC) celebrates its 15th anniversary this year with a third consecutive five-year renewal of its federal research grant.

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.